Get startedLog in
    Picture of Alligator Bioscience AB logo

    ATORX — Alligator Bioscience AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101

    Picture of Alligator Bioscience AB logoAlligator Bioscience AB
    20/03/2025 14:01
    March 20 (Reuters) - Alligator Bioscience AB ATORX.ST:

ALLIGATOR BIOSCIENCE ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR HLX22/AC101 IN GASTRIC CANCER

UNDER TERMS OF LICENSE AGREEMENT, ALLIGATOR IS ENTITLED TO 35% OF ABCLON'S REVENUE FROM SUBLICENSE AGREEMENT WITH HENLIUS

Source text: ID:nMFNmzNQm

Further company coverage: ATORX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Alligator Bioscience AB

    See all news